NCT03715634 - Study of a Novel Subcutaneous Depot Formulation of Buprenorphine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions

Opioid-use Disorder

Interventions

DRUG

INDV-6200

Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo

DRUG

Placebo

Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo

DRUG

SL Buprenorphine

All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability

DRUG

Nalorex

Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine

Trial Locations (1)

Quotient Sciences, Ruddington